Zhao Jing, Mysona Barbara A, Qureshi Azam, Kim Lily, Fields Taylor, Gonsalvez Graydon B, Smith Sylvia B, Bollinger Kathryn E
James and Jean Culver Vision Discovery Institute Augusta, Georgia, United States 2Department of Ophthalmology, Medical College of Georgia, Georgia Regents University, Augusta, Georgia, United States 3Department of Cellular Biology and Anatomy, Medical Col.
James and Jean Culver Vision Discovery Institute Augusta, Georgia, United States 2Department of Ophthalmology, Medical College of Georgia, Georgia Regents University, Augusta, Georgia, United States.
Invest Ophthalmol Vis Sci. 2016 Feb;57(2):453-61. doi: 10.1167/iovs.15-18565.
To evaluate, in vivo, the effects of the sigma-1 receptor (σR1) agonist, (+)-pentazocine, on N-methyl-D-aspartate (NMDA)-mediated retinal excitotoxicity.
Intravitreal NMDA injections were performed in C57BL/6J mice (wild type [WT]) and σR1-/- (σR1 knockout [KO]) mice. Fellow eyes were injected with phosphate-buffered saline (PBS). An experimental cohort of WT and σR1 KO mice was administered (+)-pentazocine by intraperitoneal injection, and untreated animals served as controls. Retinas derived from mice were flat-mounted and labeled for retinal ganglion cells (RGCs). The number of RGCs was compared between NMDA and PBS-injected eyes for all groups. Apoptosis was assessed using TUNEL assay. Levels of extracellular-signal-regulated kinases (ERK1/2) were analyzed by Western blot.
N-methyl-D-aspartate induced a significant increase in TUNEL-positive nuclei and a dose-dependent loss of RGCs. Mice deficient in σR1 showed greater RGC loss (≈80%) than WT animals (≈50%). (+)-Pentazocine treatment promoted neuronal survival, and this effect was prevented by deletion of σR1. (+)-Pentazocine treatment resulted in enhanced activation of ERK at the 6-hour time point following NMDA injection. The (+)-pentazocine-induced ERK activation was diminished in σR1 KO mice.
Targeting σR1 activation prevented RGC death while enhancing activation of the mitogen-activated protein kinase (MAPK), ERK1/2. Sigma-1 receptor is a promising therapeutic target for retinal neurodegenerative diseases.
在体内评估σ-1受体(σR1)激动剂(+)-喷他佐辛对N-甲基-D-天冬氨酸(NMDA)介导的视网膜兴奋性毒性的影响。
对C57BL/6J小鼠(野生型[WT])和σR1基因敲除(σR1-/-,σR1 KO)小鼠进行玻璃体内注射NMDA。对侧眼注射磷酸盐缓冲盐水(PBS)。通过腹腔注射给予WT和σR1 KO小鼠实验队列(+)-喷他佐辛,未治疗的动物作为对照。将从小鼠获得的视网膜进行平铺固定,并标记视网膜神经节细胞(RGCs)。比较所有组中NMDA注射眼和PBS注射眼的RGCs数量。使用TUNEL法评估细胞凋亡。通过蛋白质印迹分析细胞外信号调节激酶(ERK1/2)的水平。
N-甲基-D-天冬氨酸诱导TUNEL阳性细胞核显著增加以及RGCs呈剂量依赖性损失。缺乏σR1的小鼠比WT动物表现出更大的RGC损失(约80%)(约50%)。(+)-喷他佐辛治疗促进神经元存活,并且这种作用通过删除σR1而被阻止。(+)-喷他佐辛治疗导致NMDA注射后6小时时间点ERK的激活增强。在σR1 KO小鼠中,(+)-喷他佐辛诱导的ERK激活减弱。
靶向σR1激活可防止RGC死亡,同时增强丝裂原活化蛋白激酶(MAPK)ERK1/2的激活。σ-1受体是视网膜神经退行性疾病有前景的治疗靶点。